Improving Access and Delivery of CAR T-cells and Bispecific Antibodies in the Community

Building Community Cellular Therapy Programs

• 💡 Starting a new cellular therapy program requires careful planning, especially for sites without prior transplant or CAR T experience.
• ✅ Overcoming logistical barriers is crucial, such as establishing a strong team and managing patient monitoring and potential side effects like cytokine release syndrome or neurotoxicity.

The Importance of Hospital Partnerships

• 🏥 Collaboration with hospital staff is essential for managing patients, including ICU physicians, subspecialty consultants, and emergency room personnel.
• 🗺️ Expanding access means bringing these therapies closer to patients who may live far from academic centers, reducing travel burden.

Bridging the Gap Between Academic and Community Centers

• 🤝 Partnerships between experienced and new sites are vital for sharing knowledge and providing the necessary support for safe delivery of these complex therapies.
• 📈 Academic centers face increasing patient burden, especially with the expansion of CAR T and bispecifics into new indications like autoimmune diseases and solid tumors.

Future of CAR T and Bispecific Therapies

• 🚀 CAR T and bispecifics are here to stay and will continue to expand, necessitating more community sites to help co-manage patients.
• 🎯 Identifying capable community sites with proven safety, efficacy, and efficiency records is key to safely broadening access.